Welcome to our dedicated page for Hca Healthcare SEC filings (Ticker: HCA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The HCA Healthcare, Inc. (NYSE: HCA) SEC filings page provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. HCA Healthcare is a Nashville-based provider of healthcare services with 191 hospitals and approximately 2,500 ambulatory sites of care, and its filings offer detail on how it finances and governs this network, as well as how it reports operating results to shareholders.
For this issuer, Form 10-K annual reports and Form 10-Q quarterly reports are central sources for information on the performance of its general medical and surgical hospitals and related ambulatory facilities. These filings typically include discussions of segment operations, risk factors relevant to healthcare services, and descriptions of the company’s learning health system approach. On Stock Titan, AI-powered summaries can help explain key sections of lengthy 10-K and 10-Q documents in more accessible language.
HCA Healthcare also uses Form 8-K to report material events. Recent 8-Ks have described items such as the public offering of senior notes by HCA Inc., the company’s direct, wholly owned subsidiary, including the terms of the notes, related indentures and covenants, and the planned redemption of existing senior notes. Other 8-K filings have announced quarterly results, cash dividend declarations on HCA common stock, and changes in the Board of Directors.
Debt investors may focus on filings that describe senior notes, indentures and guarantees, including covenants that limit liens, sale and lease-back transactions, or major corporate reorganizations. Equity investors may review proxy materials and compensation disclosures, along with periodic reports, to understand governance structures and board committee responsibilities, such as the Audit and Compliance Committee and the Patient Safety and Quality of Care Committee.
Through Stock Titan, users can view real-time updates from EDGAR, see insider-related forms such as Form 4 when available, and rely on AI-generated highlights to quickly identify notable changes, obligations and events in HCA Healthcare’s SEC reporting history.
The Vanguard Group filed an Amendment No. 8 to Schedule 13G/A reporting zero beneficial ownership of HCA Healthcare Inc. common stock. The filing states Vanguard completed an internal realignment on January 12, 2026 and certain subsidiaries will report beneficial ownership separately in reliance on SEC Release No. 34-39538. The filing lists 0 shares and 0% ownership and includes a signed certification by Ashley Grim, Head of Global Fund Administration.
HCA Healthcare, Inc. is holding its 2026 annual meeting of stockholders as a virtual-only webcast on April 23, 2026 at 2:00 p.m. CDT. Stockholders of record at the close of business on February 23, 2026, when 223,568,966 common shares were outstanding, may vote.
Items up for vote include electing directors, ratifying Ernst & Young LLP as independent auditor for 2026, an advisory say‑on‑pay resolution, and two stockholder proposals on a report about healthcare consequences and on shareholders’ right to act by written consent.
The proxy also details HCA’s governance structure, committee composition, and extensive corporate responsibility efforts, including operating 190 hospitals and numerous outpatient facilities, handling about 47 million patient encounters in 2025, providing an estimated $4.5 billion of uncompensated care, and paying approximately $33 billion in payroll and benefits to about 320,000 colleagues.
HCA Healthcare, Inc. adopted a 2026 Executive Officer Performance Excellence Program that pays cash performance awards to executive officers based on financial and quality results. Awards are weighted 80% on EBITDA targets and 20% on quality metrics covering infections and sepsis, complications and mortality, and care experience.
For EBITDA, payouts range from 25% of the EBITDA portion at threshold performance to 200% at maximum performance, with 100% at target. For each quality metric, payouts range from 0% at or below threshold to 200% at maximum, but no quality payout is made if actual EBITDA is less than 90% of the EBITDA target. The Compensation Committee may adjust metrics and results for unusual events, and awards are subject to discretionary and mandatory clawbacks, including in the case of restated results or specified misconduct. HCA also disclosed that director Robert J. Dennis will not stand for re-election and will retire from the Board at the April 23, 2026 annual meeting.
HCA Healthcare EVP & Chief Legal & Admin Officer Michael R. McAlevey reported a mix of equity transactions involving company stock. On February 13, 2026, he exercised 5,000 Stock Appreciation Rights, receiving 5,000 shares of Common Stock at an exercise price of $236.61 per share. To cover associated tax obligations, 3,306 shares of Common Stock were disposed of at $540.29 per share through a tax-withholding transaction, rather than an open-market sale. On February 18, 2026, he completed an open-market sale of 1,694 shares of Common Stock at an average price of $533.3747 per share, leaving him with 8,853 shares of directly owned Common Stock afterward. The filing also notes indirect holdings of 2,111 shares held by a 2024 GRAT and 26 shares held in a fully managed account; for the managed account, he has no investment authority and disclaims beneficial ownership except to the extent of any pecuniary interest.
HCA Healthcare SVP & Controller Christopher F. Wyatt reported several stock transactions. On February 10, 2026, he acquired 3,350 shares of common stock at $0, reflecting the vesting of performance share units granted on January 30, 2023 and tied to cumulative 2023–2025 earnings per share. Based on the company’s EPS performance, the award vested at 200% of the 1,675 units granted.
Also on February 10, 1,034 shares were disposed of at $502.05 to cover tax obligations. On February 11, 2026, Wyatt executed an open‑market sale of 4,000 shares at $505 per share. After these transactions, he directly owned 44,379 shares of HCA Healthcare common stock.
HCA Healthcare SVP & Chief Nurse Executive Erica Rossitto reported equity compensation activity. On February 10, 2026, she acquired 1,676 shares of HCA common stock at $0 per share from the vesting of performance share units. On the same date, 418 shares at $502.05 per share were withheld and disposed of to cover tax obligations, leaving her with 10,407 directly held shares.
The vested shares arose from an original grant of 838 performance share units made on January 30, 2023. These units could vest between 0% and 200% based on cumulative earnings per share performance for fiscal years 2023–2025, and the company’s results led to vesting at 200% of the units granted.
HCA Healthcare executive Michael R. McAlevey reported equity compensation activity in company common stock. On February 10, 2026, he acquired 8,372 shares at $0 per share as a grant tied to previously awarded performance share units. On the same date, 3,006 shares were withheld at $502.05 per share to satisfy tax obligations, leaving him with 8,853 directly owned shares. The filing also shows 2,111 shares held indirectly through a 2024 GRAT and 26 shares in a fully managed account over which he has no investment authority and for which he disclaims beneficial ownership beyond any pecuniary interest.
HCA Healthcare EVP and CFO Mike A. Marks reported equity compensation activity involving HCA common stock. On February 10, 2026, he acquired 5,026 shares at $0 per share in a grant classified as an award.
On the same date, 1,690 shares of common stock were disposed of at $502.05 per share to satisfy tax obligations through share withholding, leaving 3,336 directly owned shares. The filing also shows 43,240 shares held indirectly by the MAM 2020 Trust and 26,500 shares held indirectly by the LAM 2020 Trust.
A footnote explains this grant stems from 2,513 performance share units awarded on January 30, 2023, which could vest from zero to double the units based on 2023-2025 cumulative earnings per share. Based on company performance, 200% of the units vested.